Calliditas Therapeutics AB
STO:CALTX

Watchlist Manager
Calliditas Therapeutics AB Logo
Calliditas Therapeutics AB
STO:CALTX
Watchlist
Price: 208 SEK 0.87% Market Closed
Market Cap: 12.5B SEK
Have any thoughts about
Calliditas Therapeutics AB?
Write Note

Calliditas Therapeutics AB
Cash from Operating Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Calliditas Therapeutics AB
Cash from Operating Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Operating Activities CAGR 3Y CAGR 5Y CAGR 10Y
Calliditas Therapeutics AB
STO:CALTX
Cash from Operating Activities
-kr244.9m
CAGR 3-Years
21%
CAGR 5-Years
-8%
CAGR 10-Years
N/A
Camurus AB
STO:CAMX
Cash from Operating Activities
kr314.8m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
S
Swedencare AB (publ)
STO:SECARE
Cash from Operating Activities
kr413.9m
CAGR 3-Years
73%
CAGR 5-Years
69%
CAGR 10-Years
N/A
IRLAB Therapeutics AB
STO:IRLAB A
Cash from Operating Activities
-kr164.9m
CAGR 3-Years
-23%
CAGR 5-Years
-18%
CAGR 10-Years
N/A
Moberg Pharma AB (publ)
STO:MOB
Cash from Operating Activities
-kr33.2m
CAGR 3-Years
-29%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
I
InDex Pharmaceuticals Holding AB
STO:FLERIE
Cash from Operating Activities
-kr71.3m
CAGR 3-Years
7%
CAGR 5-Years
0%
CAGR 10-Years
N/A
No Stocks Found

Calliditas Therapeutics AB
Glance View

Market Cap
12.5B SEK
Industry
Pharmaceuticals

Calliditas Therapeutics AB clinical-stage biopharmaceutical company. The company is headquartered in Stockholm, Stockholm. The company went IPO on 2018-06-29. The company is focused on the development and commercialization of its product candidate Nefecon, a treatment for patients with inflammatory kidney disease (IgA nephropathy) who are at risk of progressing to renal failure. Nefecon is derived from the TARGIT technology, in which the capsule containing the active drug substance is coated in a way that the capsule remains intact as it passes through the stomach and intestine until it reaches the lower small intestine, where the release of content takes place. Nefeco combines time lag effect with a concentrated release of the active substance budesonide, within a designated target area.

CALTX Intrinsic Value
725.13 SEK
Undervaluation 71%
Intrinsic Value
Price

See Also

What is Calliditas Therapeutics AB's Cash from Operating Activities?
Cash from Operating Activities
-244.9m SEK

Based on the financial report for Jun 30, 2024, Calliditas Therapeutics AB's Cash from Operating Activities amounts to -244.9m SEK.

What is Calliditas Therapeutics AB's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 5Y
-8%

Over the last year, the Cash from Operating Activities growth was 15%. The average annual Cash from Operating Activities growth rates for Calliditas Therapeutics AB have been 21% over the past three years , -8% over the past five years .

Back to Top